[et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_post_title meta=”off” featured_image=”off” admin_label=”Project Title” _builder_version=”3.0.90″ global_module=”825″ saved_tabs=”all” global_colors_info=”{}”][\/et_pb_post_title][et_pb_toggle title=”The Research” open=”on” open_toggle_background_color=”#ffffff” closed_toggle_background_color=”#c5e6f7″ icon_color=”#d52f43″ open_icon_color=”#d52f43″ _builder_version=”4.27.4″ title_font=”|on|||” title_text_align=”justify” hover_enabled=”0″ border_color_all=”#e0d4e9″ use_border_color=”on” saved_tabs=”all” global_colors_info=”{}” sticky_enabled=”0″]Finocchiaro G. – Project funded until 2020<\/p>\n
Current standard treatment of glioblastoma multiforme (GBM) is based on the surgical resection of the tumour mass followed by radio- and chemotherapy (Stupp et al., 2005). In spite of novel therapeutic approaches, the prognosis remains dismal and relapse is almost inevitable. We thus clearly need to produce long term, well tolerated and tumourspecific treatments able to eliminate the (remaining) tumour cells infiltrated in the nearby brain areas.
\nThe immune system provides important tools in this direction. Preclinical trials for the development of vaccines against high-grade gliomas, based on the use of potent immune cells i.e. dendritic cells, exposed to a mix of tumour antigens deriving from the glioma (Pellegatta et al., 2005 and 2006), have been carried out in both rat models (Liau et al., 1999; Siesjo et al., 1996; Witham et al., 2002) and mouse models (Akasaki et al., 2001; Heimberger et al., 2000; Insug et al., 2002; Kikuchi et al., 2002; Ni et al., 2001; Okada et al., 1998), showing their capacity to produce a tumour-specific immune response.
\nMature DC with autologous tumour lysate have been used to treat patients with relapsed malignant tumours (De Vleeschouwer et al., 2004; Rutkowski et al., 2004; Wheeler et al., 2004; Yamanaka et al., 2003; Yu et al., 2004); no significant adverse effects have been reported. In Italy we have been able to repeat this experience with the treatment of six patients affected by relapsing GBM, using dendritic cells prepared at the Istituto Neurologico Besta. Median survival of these patients from time of relapse is currently of 11,5 months (Finocchiaro et al, manuscript in preparation).
\nThe results of the use of immunotherapy on GBM patients are promising, but further investigation is necessary to identify a safe and more effective combination of immunotherapy with radio- and chemotherapy after tumour resection.<\/p>\n
Dott. Gaetano Finocchiaro, M.D.<\/p>\n
Director, Unit Neurology 8- Molecular Neuro-Oncology
\nDirector, Department of Neuro-Oncology
\nFondazione IRCCS Istituto Neurologico Besta
\nvia Celoria 11, 20133 Milano
\nPhone +39 02 2394 2769
\nfax +39 02 2394 2453<\/p>\n
Group-leader IFOM-IEO Campus
\nvia Adamello 16, 20139 Milano
\nPhone +39 02 9437 5113<\/p>\n
E mail: finocchiaro@istituto-besta.it[\/et_pb_toggle][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_toggle title=”Evolution” open_toggle_background_color=”#ffffff” closed_toggle_background_color=”#c5e6f7″ icon_color=”#d52f43″ open_icon_color=”#d52f43″ admin_label=”toggle Gli sviluppi” _builder_version=”4.16″ title_font=”|on|||” title_text_align=”justify” border_color_all=”#e0d4e9″ use_border_color=”on” saved_tabs=”all” global_colors_info=”{}”]<\/p>\n
Serena Pellegatta, Barbara Savoldo, Natalia Di Ianni, Cristina Corbetta, Yuhui Chen, Monica Patan\u00e9, Chuang Sun, Bianca Pollo, Soldano Ferrone, Francesco DiMeco, Gaetano Finocchiaro, Gianpietro Dotti Serena Pellegatta, Marica Eoli, Valeria Cuccarini, Elena Anghileri, Bianca Pollo, Sara Pessina, Simona Frigerio, Maura Servida, Lucia Cuppini, Carlo Antozzi, Stefania Cuzzubbo, Cristina Corbetta, Rosina Paterra, Francesco Acerbi, Paolo Ferroli, Francesco DiMeco, Laura Fariselli, Eugenio A. Parati, Maria Grazia Bruzzone & Gaetano Finocchiaro Serena Pellegatta, Pietro Luigi Poliani, Elena Stucchi, Daniela Corno, Chiara Agnese Colombo, Francesca Orzan, Maria Ravanini, and Gaetano Finocchiaro. Gabriele Cantini, Federica Pisati, Sara Pessina, Gaetano Finocchiaro and Serena Pellegatta. Serena Pellegatta, Marica Eoli, Simona Frigerio, Carlo Antozzi, Maria Grazia Bruzzone, Gabriele Cantini, sara Nava, Elena Anghileri, Lucia Cuppini, Valeria Cuccarini, Emilio Ciusani, Marta Dossena, Bianca Pollo, Renato Mantegazza, Eugenio A. Parati and Gaetano Finocchiaro. Pellegatta S, Poliani PL, Corno D, Menghi F, Ghielmetti F, Suarez-Merino B, Caldera V, Nava S, Ravanini M, Facchetti F, Bruzzone MG, Finocchiaro G. Gabriele Cantini, Federica Pisati, Alfonso Mastropietro, V\u00e9ronique Frattini, Yoichiro Iwakura, Gaetano Finocchiaro, Serena Pellegatta Gabriele Cantini, Federica Pisati, Sara Pessina, Gaetano Finocchiaro and Serena Pellegatta V\u00e9ronique Frattini, Federica Pisati, Maria Carmela Speranza, Pietro Luigi Poliani, Gianmaria Frig\u00e9, Gabriele Cantini, Dimos Kapetis, Manuela Cominelli, Alessandra Rossi, Gaetano Finocchiaro and Serena Pellegatta Antonella De Rosa, Serena Pellegatta, Marco Rossi, Patrizia Tunici, Letizia Magnoni, Maria Carmela Speranza, Federico Malusa, Vincenzo Miragliotta, Elisa Mori, Gaetano Finocchiaro, Annette Bakker
\nConstitutive and TNF?-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy.
\nScience Translational Medicine, 10, eaao2731 (2018) 28 February 2018.
\ndownload pdf<\/a> (85 KB)<\/p>\n
\nSurvival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide
\nOncoImmunology, Volume 7, 2018 – Issue 4
\ndownload pdf<\/a> (2 MB)<\/p>\n
\nIntra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment.
\nNeuro-Oncology 12(4) -377-388, 2010.
\ndownload pdf<\/a> (72 KB)<\/p>\n
\nImmunotherapy against the radial glia marker GLAST effectively triggers specific antitumor effectors without autoimmunity.
\nOncoimmunology 1:6, 884-893; September 2012.
\ndownload pdf<\/a> (163 KB)<\/p>\n
\nThe natural killer cell response and tumor debulking are associated with prolonged serviva in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates.
\nOncoimmunology 2:3, e23401; March 2013.
\ndownload pdf<\/a> (155 KB)<\/p>\n
\nNeurospheres Enriched in Cancer Stem-Like Cells Are Highly Effective in Eliciting a Dendritic Cell-Mediated Immune Response against Malignant Gliomas.
\nCancer Res. 2006 Nov 1;66(21):10247-52.
\ndownload pdf<\/a> (569 KB)<\/p>\n
\nA critical role for regulatory T cells in driving cytokines profiles of Th17 cells and their modulation of glioma microenvironment.
\nCancer Immunol. Immunother. 2011 Jul DOI 10.1007\/s00262-011-1069-4.
\ndownload pdf<\/a> (143 KB)<\/p>\n
\nImmunotherapy against the radial glia marker GLAST effectively triggers specific antitumor effectors without autoimmunity
\nOncoImmunology 1:8, 1-10; November 2012; \u00a9 2012 Landes Bioscience.
\ndownload pdf<\/a> (198 KB)<\/p>\n
\nFOXP3, a novel glioblastoma oncosuppressor, affects proliferation and migration
\nOncotarget, Advance Publications, September 2012.
\ndownload pdf<\/a> (591 KB)<\/p>\n
\nA Radial Glia Gene Marker, Fatty Acid Binding Protein 7 (FABP7), Is Involved in Proliferation and Invasion of Glioblastoma Cells
\nPLOS ONE, December 2012, Volume 7, Issue 12, e52113.
\ndownload pdf<\/a> (140 KB)<\/p>\n